Mar 16, 2025 Laplace Interventional: $22M Series C Fundraise
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
November 24, 2024 Dr. Kashish Goel presents on Laplace TTVR System at PCR London Valves
Laplace Interventional Inc. Announces Series C Financing of $22M for its Transcatheter Tricuspid Valve Technology
November 24, 2024 Dr. Kashish Goel presents on Laplace TTVR System at PCR London Valves
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
November 24, 2024 Dr. Kashish Goel presents on Laplace TTVR System at PCR London Valves
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
June 6, 2024 Dr. Thomas Waggoner presents on Laplace TTVR System FIH results at New York Valves 2024
June 6, 2024 Dr. Thomas Waggoner presents on Laplace TTVR System FIH results at New York Valves 2024
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
Feb 26, 2024 Laplace Interventional begins the US EFS of their TTVR system
June 6, 2024 Dr. Thomas Waggoner presents on Laplace TTVR System FIH results at New York Valves 2024
Feb 26, 2024 Laplace Interventional begins the US EFS of their TTVR system
Laplace Interventional Inc. Announces Successful First in Human Procedure in Early Feasibility Study of its Transcatheter Tricuspid Valve Replacement Device.
July 24, 2023 Laplace Interventional: $12.9M Series B Fundraise
June 6, 2024 Dr. Thomas Waggoner presents on Laplace TTVR System FIH results at New York Valves 2024
Feb 26, 2024 Laplace Interventional begins the US EFS of their TTVR system
The Series B financing was co-led by ShangBay Capital along with Features Capital in addition to participation from Engage Venture Partners, JWC Ventures and a global strategic investor. Laplace Interventional plans to use the funds raised from this round to pursue their First-in-Human (FIH) and clinical feasibility evaluation of its transcatheter valve system.
Sep 1, 2021: Laplace Interventional: $7.9M Series A Fundraise
Sep 1, 2021: Laplace Interventional: $7.9M Series A Fundraise
Sep 1, 2021: Laplace Interventional: $7.9M Series A Fundraise
The Series A was led by a major strategic investor along with a significant investment from ShangBay Capital as well as other investors. Laplace Interventional plans to use the funds raised from this round towards achieving its preclinical milestones.